Metastat Inc (MTST) 1.3000 $MTST
Celgene Corporation (NASDAQ: CELG) CMO Joins MetaStat Inc (OTCQB: MTST) Board
ACCESSWIRE - Wed Apr 27, 9:26AM CDT
NEW YORK, NY / ACCESSWIRE / April 27, 2016 / Development stage biotech company MetaStat Inc (OTCQB: MTST) just announced a high-profile, and potentially game changing addition to its board of directors. As of April 26, 2016, Jerome B. Zeldis, M.D., Ph.D, Chief Medical Officer of Celgene Corporation (NASDAQ:CELG) and Chief Executive Officer of Celgene Global Health, will join the Metastat board as its vice chairman. For a company the size of MetaStat, which had a market capitalization of a little over $3.42 million at last count, the addition of an industry professional with the standing of Zeldis is a validation of the potential of its lead diagnostics technology - something we will touch on in a little more detail shortly.
ALQA: 1.10 (-0.01), CELG: 112.55 (+0.38), CELGZ: 1.11 (-0.12)
MetaStat Appoints Jerome B. Zeldis, M.D., Ph.D. to its Board of Directors
BusinessWire - Wed Apr 27, 6:30AM CDT
MetaStat, Inc. (OTCQB:MTST), a molecular diagnostic company, today announced the appointment of Jerome B. Zeldis, M.D., Ph.D. to serve as Vice Chairman of the company's Board of Directors. Dr. Zeldis is the Chief Medical Officer of Celgene Corporation (NASDAQ: CELG) and Chief Executive Officer of Celgene Global Health.
CELG: 112.55 (+0.38), CELGZ: 1.11 (-0.12)
MetaStat Announces Successful Analytical Validation of its MenaCalc(TM) Cancer Diagnostic Platform
BusinessWire - Tue Jan 26, 6:53AM CST
MetaStat, Inc. (OTCQB: MTST), a molecular diagnostic company, today announced the successful completion of an analytical validation study of its MenaCalc(TM) clinical test, which demonstrated strong overall assay performance and precision with mean coefficient of variation (%CV) of only 2.3% (Range 0.07-6.95). MenaCalc(TM) is a next generation driver-based prognostic test to predict the risk of developing cancer metastasis in patients with invasive breast cancer, squamous cell carcinoma of the lung and a number of additional epithelial-based cancer tumors. The MenaCalc(TM) results, reported as a MenaCalc(TM) Score, better inform physicians in making treatment decisions to enhance outcomes.
MetaStat Presents Positive Analytical Validation Data for MetaSite Breast(TM) Cancer Diagnostic Test
BusinessWire - Wed Dec 02, 1:42PM CST
MetaStat, Inc. (OTCQB:MTST), a molecular diagnostic company, today presented positive results from an analytical validation study demonstrating the analytical accuracy, reproducibility, and precision of its MetaSite Breast(TM) test at the Tumor Metastasis meeting of the American Association for Cancer Research (AACR) in Austin, Texas.
MetaStat Receives CLIA Certification from the Centers for Medicare and Medicaid Services
BusinessWire - Mon Nov 30, 7:30AM CST
MetaStat, Inc. (OTCQB:MTST), a molecular diagnostic company, today announced certification from the U.S. Department of Health and Human Services' Centers for Medicare and Medicaid Services (CMS) under the Clinical Laboratory Improvement Amendments (CLIA) of 1988 for its next-generation digital immunohistochemistry laboratory in Boston, Massachusetts.
MetaStat Announces Reverse Stock Split in Preparation for a Proposed Uplisting to a National Market
BusinessWire - Wed Oct 07, 3:56PM CDT
MetaStat, Inc. (OTCQB:MTST), a molecular diagnostic company, today announced that effective 7:00 a.m. Eastern Standard Time, October 8, 2015, the company will implement a 1-for-15 reverse split of its common stock for the purpose of qualifying for the minimum stock price requirement for listing on a national securities exchange, such as the NASDAQ Capital Market or NYSE Market. The company's common stock will begin trading on a post-split basis on the OTCQB under the temporary symbol "MTSTD" effective with the open of trading tomorrow, October 8, 2015.
Benchmark Securities Initiates Coverage of MetaStat, Inc. with a Speculative Buy Rating
ACCESSWIRE - Tue Oct 06, 1:23PM CDT
NEW YORK, NY / ACCESSWIRE / October 6, 2015 / Market Exclusive announces that Benchmark Securities has initiated coverage of MetaStat, Inc. (OTCQB: MTST) with a Speculative Buy rating and a 12-month price target of $1 per share.
Zacks Small-Cap Research: "MTST: Lab Receives State License, Last Major Before CLIA Certification"
ACCESSWIRE - Tue Sep 29, 9:32AM CDT
NEW YORK, NY / ACCESSWIRE / September 29, 2015 / Market Exclusive announces that Zacks Small-Cap Research has reiterated a Buy rating of MetaStat, Inc. (OTCQB: MTST) to with a 12-month price target of $0.75 per share. The analyst note was published following MetaStat's newly announced Massachusetts state clinical laboratory license, a commercial milestone towards attaining CLIA certification.
MetaStat Announces Positive Topline Results of a MetaSite Breast(TM) Prognostic Study in Invasive Breast Cancer
BusinessWire - Wed Sep 23, 2:22PM CDT
MetaStat, Inc. (OTCQB:MTST), a molecular diagnostic company, today announced positive preliminary results from a study of MetaSite Breast(TM) in patients with ER-positive, HER2-negative early stage invasive breast cancer. The prognostic study met its prospectively defined primary endpoint. It demonstrated the MetaSite Breast(TM) Score is significantly and directly associated with increased risk of distant metastasis in ER-positive, HER2-negative invasive breast cancer for both high (>35 MetaSites) versus low (<12 MetaSites) MetaSite scores (OR = 3.4; 95%CI = 2.8-4.1; P=0.0002) as well as between intermediate (12-35 MetaSites) and low MetaSite scores (OR=3.24; 95%CI = 2.6-3.9; P=0.0006).
Award Winning Cancer Researcher, Dr. Bruce R. Zetter, Joins MetaStat, Inc. Scientific and Clinical Advisory Board
Marketwired - Thu Sep 10, 7:29AM CDT
MetaStat, Inc. (OTCQB: MTST), a molecular diagnostics company focused on developing and commercializing tissue-based diagnostic tests for prediction of cancer metastasis, announced today Bruce R. Zetter, PhD has joined the company's Scientific and Clinical Advisory Board. Dr. Zetter is the Charles Nowiszewski Professor in the Departments of Cell Biology and Surgery at Harvard Medical School. He is an internationally recognized leader in cancer research, tumor progression, cancer diagnosis, cancer metastasis, and tumor angiogenesis.
MetaStat, Inc. Appoints Michael J. Donovan, PhD, MD as Chief Medical Officer
BusinessWire - Mon Aug 17, 8:18AM CDT
MetaStat, Inc. (OTCQB: MTST), a molecular diagnostic company focused on developing and commercializing epigenetic diagnostic tests for early and reliable prediction of systemic cancer metastasis, today announced the appointment of Michael J. Donovan, PhD, MD as acting Chief Medical Officer.
MetaStat Raises Additional Capital in Private Placement
BusinessWire - Wed Aug 05, 6:30AM CDT
MetaStat, Inc. (OTCQB:MTST), a molecular diagnostic company developing and commercializing epigenetic diagnostic tests for early and reliable prediction of systemic cancer metastasis, announced effective July 31, 2015 the closing of a private placement of promissory notes resulting in gross proceeds of $1.2 million. The financing was funded by an existing investor, Dolphin Offshore Partners, LP.
EMR 2015: The Market for Electronic Medical Records
M2 - Fri Jul 24, 4:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/46969b/emr_2015_the) has announced the addition of the "EMR 2015: The Market for Electronic Medical Records" report to their offering. This Kalorama Information report, EMR 2015: The Market for Electronic Medical Records, is the resource that companies in the electronic medical records (EMR) use for business planning, benchmarking and opportunity analysis. This 490-page report is a complete global analysis of the EMR / EHR market. The eighth annual report concluded on this topic since 2007 includes the important trends that will affect companies offering software, hardware and services related to EMR. Vendor Market Share, Physician Adoption, International Markets and Other Trends This market analysis is global, though trend analysis focuses on the US as the largest healthcare market and the most incentivized for EMR conversion. As government policy approaches the turning-point on incentives in this market, as a large shift in vendor market share occurs and new vendors play a larger role, it is an interesting time for market-watchers. How much has the market grown? How have the incentives worked? Where is physician usage now? How about hospital adoption? Where do the top vendors stand now? Kalorama answers these questions and brings sharp analysis to recent trends. MARKET PARTICIPANTS - 4Medica - ADP AdvancedMD - Allmeds - Allscripts Healthcare Solutions - Amazing Charts - Aprima Medical Software, Inc - athenahealth, Inc. - BizMatics, Inc. - Computer Programs and Systems, Inc. - CSC - CureMD - eClinicalworks - Reproduction without prior written permission, in any media now in - existence or hereafter developed, in whole or in any part, is strictly prohibited - Epic Systems Corporation - GE Healthcare - Greenway Medical Technologies - HealthFusion, Inc - Healthland - Henry Schein - McKesson Corporation - MedHost - Meditab Software Inc - Microtest LTD. - NextGen Healthcare Information Systems /Quality Systems Inc - Nextech - Nightingale Infomatix Corporation - Nuesoft Technologies Inc - Practice fusion - Quadramed Corporation - Siemens Medical Solutions - Streamline MD - Tieto - WRS Health (Waiting Room solutions) - WebPT For more information visit http://www.researchandmarkets.com/research/46...r_2015_the
MCK: 195.78 (+0.77), QSII: 11.96 (-0.24), MDRX: 12.72 (-0.27), HSIC: 161.40 (-1.47)
SeeThruEquity Initiates Coverage on MetaStat, Inc. with a Price Target of $1.23
ACCESSWIRE - Thu Jun 25, 7:31AM CDT
NEW YORK, NY / ACCESSWIRE / June 25, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has initiated coverage of MetaStat, Inc. (OTCQB: MTST) with a price target of $1.23.
MetaStat reports change in executive positions
M2 - Fri Jun 19, 3:44AM CDT
Molecular diagnostic company MetaStat (OtherOTC:MTST) revealed on Wednesday the addition of Douglas A. Hamilton as its president and chief executive officer.
MetaStat, Inc. Announces Douglas A. Hamilton Named President, Chief Executive Officer
BusinessWire - Thu Jun 18, 7:00AM CDT
MetaStat, Inc. (OTCQB:MTST), announced that Douglas A. Hamilton has been elected as President and Chief Executive Officer of the company. Mr. Hamilton has consulted for the company as acting Chief Financial Officer since August 2014.
HSP: 89.95 (-0.01)
MetaStat To Present at SeeThruEquity Conference in New York City on May 28
ACCESSWIRE - Wed May 20, 10:00AM CDT
Presentation to Be Webcast
Celgene Corporation (NASDAQ: CELG) CMO Joins MetaStat Inc (OTCQB: MTST) Board
ACCESSWIRE - Wed Apr 27, 9:26AM CDT
NEW YORK, NY / ACCESSWIRE / April 27, 2016 / Development stage biotech company MetaStat Inc (OTCQB: MTST) just announced a high-profile, and potentially game changing addition to its board of directors. As of April 26, 2016, Jerome B. Zeldis, M.D., Ph.D, Chief Medical Officer of Celgene Corporation (NASDAQ:CELG) and Chief Executive Officer of Celgene Global Health, will join the Metastat board as its vice chairman. For a company the size of MetaStat, which had a market capitalization of a little over $3.42 million at last count, the addition of an industry professional with the standing of Zeldis is a validation of the potential of its lead diagnostics technology - something we will touch on in a little more detail shortly.
ALQA: 1.10 (-0.01), CELG: 112.55 (+0.38), CELGZ: 1.11 (-0.12)
MetaStat Appoints Jerome B. Zeldis, M.D., Ph.D. to its Board of Directors
BusinessWire - Wed Apr 27, 6:30AM CDT
MetaStat, Inc. (OTCQB:MTST), a molecular diagnostic company, today announced the appointment of Jerome B. Zeldis, M.D., Ph.D. to serve as Vice Chairman of the company's Board of Directors. Dr. Zeldis is the Chief Medical Officer of Celgene Corporation (NASDAQ: CELG) and Chief Executive Officer of Celgene Global Health.
CELG: 112.55 (+0.38), CELGZ: 1.11 (-0.12)
MetaStat Announces Successful Analytical Validation of its MenaCalc(TM) Cancer Diagnostic Platform
BusinessWire - Tue Jan 26, 6:53AM CST
MetaStat, Inc. (OTCQB: MTST), a molecular diagnostic company, today announced the successful completion of an analytical validation study of its MenaCalc(TM) clinical test, which demonstrated strong overall assay performance and precision with mean coefficient of variation (%CV) of only 2.3% (Range 0.07-6.95). MenaCalc(TM) is a next generation driver-based prognostic test to predict the risk of developing cancer metastasis in patients with invasive breast cancer, squamous cell carcinoma of the lung and a number of additional epithelial-based cancer tumors. The MenaCalc(TM) results, reported as a MenaCalc(TM) Score, better inform physicians in making treatment decisions to enhance outcomes.
MetaStat Presents Positive Analytical Validation Data for MetaSite Breast(TM) Cancer Diagnostic Test
BusinessWire - Wed Dec 02, 1:42PM CST
MetaStat, Inc. (OTCQB:MTST), a molecular diagnostic company, today presented positive results from an analytical validation study demonstrating the analytical accuracy, reproducibility, and precision of its MetaSite Breast(TM) test at the Tumor Metastasis meeting of the American Association for Cancer Research (AACR) in Austin, Texas.
MetaStat Receives CLIA Certification from the Centers for Medicare and Medicaid Services
BusinessWire - Mon Nov 30, 7:30AM CST
MetaStat, Inc. (OTCQB:MTST), a molecular diagnostic company, today announced certification from the U.S. Department of Health and Human Services' Centers for Medicare and Medicaid Services (CMS) under the Clinical Laboratory Improvement Amendments (CLIA) of 1988 for its next-generation digital immunohistochemistry laboratory in Boston, Massachusetts.
MetaStat Announces Reverse Stock Split in Preparation for a Proposed Uplisting to a National Market
BusinessWire - Wed Oct 07, 3:56PM CDT
MetaStat, Inc. (OTCQB:MTST), a molecular diagnostic company, today announced that effective 7:00 a.m. Eastern Standard Time, October 8, 2015, the company will implement a 1-for-15 reverse split of its common stock for the purpose of qualifying for the minimum stock price requirement for listing on a national securities exchange, such as the NASDAQ Capital Market or NYSE Market. The company's common stock will begin trading on a post-split basis on the OTCQB under the temporary symbol "MTSTD" effective with the open of trading tomorrow, October 8, 2015.
Benchmark Securities Initiates Coverage of MetaStat, Inc. with a Speculative Buy Rating
ACCESSWIRE - Tue Oct 06, 1:23PM CDT
NEW YORK, NY / ACCESSWIRE / October 6, 2015 / Market Exclusive announces that Benchmark Securities has initiated coverage of MetaStat, Inc. (OTCQB: MTST) with a Speculative Buy rating and a 12-month price target of $1 per share.
Zacks Small-Cap Research: "MTST: Lab Receives State License, Last Major Before CLIA Certification"
ACCESSWIRE - Tue Sep 29, 9:32AM CDT
NEW YORK, NY / ACCESSWIRE / September 29, 2015 / Market Exclusive announces that Zacks Small-Cap Research has reiterated a Buy rating of MetaStat, Inc. (OTCQB: MTST) to with a 12-month price target of $0.75 per share. The analyst note was published following MetaStat's newly announced Massachusetts state clinical laboratory license, a commercial milestone towards attaining CLIA certification.
MetaStat Announces Positive Topline Results of a MetaSite Breast(TM) Prognostic Study in Invasive Breast Cancer
BusinessWire - Wed Sep 23, 2:22PM CDT
MetaStat, Inc. (OTCQB:MTST), a molecular diagnostic company, today announced positive preliminary results from a study of MetaSite Breast(TM) in patients with ER-positive, HER2-negative early stage invasive breast cancer. The prognostic study met its prospectively defined primary endpoint. It demonstrated the MetaSite Breast(TM) Score is significantly and directly associated with increased risk of distant metastasis in ER-positive, HER2-negative invasive breast cancer for both high (>35 MetaSites) versus low (<12 MetaSites) MetaSite scores (OR = 3.4; 95%CI = 2.8-4.1; P=0.0002) as well as between intermediate (12-35 MetaSites) and low MetaSite scores (OR=3.24; 95%CI = 2.6-3.9; P=0.0006).
Award Winning Cancer Researcher, Dr. Bruce R. Zetter, Joins MetaStat, Inc. Scientific and Clinical Advisory Board
Marketwired - Thu Sep 10, 7:29AM CDT
MetaStat, Inc. (OTCQB: MTST), a molecular diagnostics company focused on developing and commercializing tissue-based diagnostic tests for prediction of cancer metastasis, announced today Bruce R. Zetter, PhD has joined the company's Scientific and Clinical Advisory Board. Dr. Zetter is the Charles Nowiszewski Professor in the Departments of Cell Biology and Surgery at Harvard Medical School. He is an internationally recognized leader in cancer research, tumor progression, cancer diagnosis, cancer metastasis, and tumor angiogenesis.
MetaStat, Inc. Appoints Michael J. Donovan, PhD, MD as Chief Medical Officer
BusinessWire - Mon Aug 17, 8:18AM CDT
MetaStat, Inc. (OTCQB: MTST), a molecular diagnostic company focused on developing and commercializing epigenetic diagnostic tests for early and reliable prediction of systemic cancer metastasis, today announced the appointment of Michael J. Donovan, PhD, MD as acting Chief Medical Officer.
MetaStat Raises Additional Capital in Private Placement
BusinessWire - Wed Aug 05, 6:30AM CDT
MetaStat, Inc. (OTCQB:MTST), a molecular diagnostic company developing and commercializing epigenetic diagnostic tests for early and reliable prediction of systemic cancer metastasis, announced effective July 31, 2015 the closing of a private placement of promissory notes resulting in gross proceeds of $1.2 million. The financing was funded by an existing investor, Dolphin Offshore Partners, LP.
EMR 2015: The Market for Electronic Medical Records
M2 - Fri Jul 24, 4:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/46969b/emr_2015_the) has announced the addition of the "EMR 2015: The Market for Electronic Medical Records" report to their offering. This Kalorama Information report, EMR 2015: The Market for Electronic Medical Records, is the resource that companies in the electronic medical records (EMR) use for business planning, benchmarking and opportunity analysis. This 490-page report is a complete global analysis of the EMR / EHR market. The eighth annual report concluded on this topic since 2007 includes the important trends that will affect companies offering software, hardware and services related to EMR. Vendor Market Share, Physician Adoption, International Markets and Other Trends This market analysis is global, though trend analysis focuses on the US as the largest healthcare market and the most incentivized for EMR conversion. As government policy approaches the turning-point on incentives in this market, as a large shift in vendor market share occurs and new vendors play a larger role, it is an interesting time for market-watchers. How much has the market grown? How have the incentives worked? Where is physician usage now? How about hospital adoption? Where do the top vendors stand now? Kalorama answers these questions and brings sharp analysis to recent trends. MARKET PARTICIPANTS - 4Medica - ADP AdvancedMD - Allmeds - Allscripts Healthcare Solutions - Amazing Charts - Aprima Medical Software, Inc - athenahealth, Inc. - BizMatics, Inc. - Computer Programs and Systems, Inc. - CSC - CureMD - eClinicalworks - Reproduction without prior written permission, in any media now in - existence or hereafter developed, in whole or in any part, is strictly prohibited - Epic Systems Corporation - GE Healthcare - Greenway Medical Technologies - HealthFusion, Inc - Healthland - Henry Schein - McKesson Corporation - MedHost - Meditab Software Inc - Microtest LTD. - NextGen Healthcare Information Systems /Quality Systems Inc - Nextech - Nightingale Infomatix Corporation - Nuesoft Technologies Inc - Practice fusion - Quadramed Corporation - Siemens Medical Solutions - Streamline MD - Tieto - WRS Health (Waiting Room solutions) - WebPT For more information visit http://www.researchandmarkets.com/research/46...r_2015_the
MCK: 195.78 (+0.77), QSII: 11.96 (-0.24), MDRX: 12.72 (-0.27), HSIC: 161.40 (-1.47)
SeeThruEquity Initiates Coverage on MetaStat, Inc. with a Price Target of $1.23
ACCESSWIRE - Thu Jun 25, 7:31AM CDT
NEW YORK, NY / ACCESSWIRE / June 25, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has initiated coverage of MetaStat, Inc. (OTCQB: MTST) with a price target of $1.23.
MetaStat reports change in executive positions
M2 - Fri Jun 19, 3:44AM CDT
Molecular diagnostic company MetaStat (OtherOTC:MTST) revealed on Wednesday the addition of Douglas A. Hamilton as its president and chief executive officer.
MetaStat, Inc. Announces Douglas A. Hamilton Named President, Chief Executive Officer
BusinessWire - Thu Jun 18, 7:00AM CDT
MetaStat, Inc. (OTCQB:MTST), announced that Douglas A. Hamilton has been elected as President and Chief Executive Officer of the company. Mr. Hamilton has consulted for the company as acting Chief Financial Officer since August 2014.
HSP: 89.95 (-0.01)
MetaStat To Present at SeeThruEquity Conference in New York City on May 28
ACCESSWIRE - Wed May 20, 10:00AM CDT
Presentation to Be Webcast
